Lactobacillus Vaginalis Capsules for the Management of Vulvovaginal Atrophy in Young Breast Cancer Patients - Trial NCT05974449
Access comprehensive clinical trial information for NCT05974449 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital with Nanjing Medical University and is currently Not yet recruiting. The study focuses on Breast Cancer Female. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The First Affiliated Hospital with Nanjing Medical University
Timeline & Enrollment
Phase 2
Aug 01, 2023
Dec 30, 2024
Primary Outcome
Vaginal PH,Functional Assessment of Breast Cancer Therapy Scale (FACT-B),Functional Assessment of Endocrine Therapy Scale (FACT-ES)
Summary
This study is a prospective, randomized controlled, phase II clinical study with a planned
 enrolment of 60 patients. The study focuses on the efficacy and safety of Lactobacillus
 vaginalis capsules for the prevention and/or treatment of vulvovaginal symptoms in young
 breast cancer patients receiving ovarian protection during chemotherapy, in order to improve
 compliance and quality of life in breast cancer patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05974449
Non-Device Trial